Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable, and many patients achieve long-term remission after frontline therapy. Advances in chemotherapy, radiation techniques and targeted ...

CURE was live on site at the the 19th Annual New York GU Cancers Congress®, where we spoke with Dr. Ulka Vaishampayan on the ...

For many people diagnosed with colorectal cancer, surgery can bring lifesaving treatment but also lasting changes.

Dr. Anastasia Tousimis explores the feasibility, risks and surgical techniques for performing NSM in radiated patients to ...

An ipsilateral breast cancer recurrence after long disease-free interval may still permit curative-intent local therapy, with ...

A Decision Score provides prognostic discrimination for 10-year locoregional recurrence, with rising score associated with higher recurrence risk after breast-conserving surgery. A Radiation ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

Among patients on q2-week chemotherapy, exercise significantly reduced overall cognitive decline, perceived cognitive impairment, and mental fatigue versus usual care. Attenuated effects with ...

Practice-changing data in endometrial cancer support checkpoint inhibitor–chemotherapy combinations, extending ...

Eyelashes provide biomechanical ocular surface protection by sensing debris and triggering the blink reflex, reducing ...

In the rapidly shifting landscape of multiple myeloma treatment, the roadmap for a patient diagnosed in 2026 looks vastly different than it did even a decade ago. In a recent interview with CURE, Dr.

Dr. Will Parsons, of Texas Children’s, discusses evolving therapies, survivorship clinics and tools like Passport For Care for long-term cancer care.